Physical inactivity has consistently been shown to be one of the most powerful, modifiable risk factors for all causes of death and disease, alongside smoking and obesity.
This interactive body map brings together scientific evidence on the links between lack of physical activity and disease.
Click on the coloured dots on the body, or choose a specific disease from the dropdown menu, or cycle through all diseases via the next and previous buttons.
To use the map, click on any of the coloured dots on the body, or choose a specific disease from the dropdown menu. You can also filter by disease or condition type.
This is the first in our package on the benefits of exercise. Read other articles in the package here.
For a copy of the data and notes on the methodology used for the calculations, please visit The Conversation’s GitHub page.
Carol Maher receives funding from the National Health and Medical Research Council and the National Heart Foundation.
Tim Olds receives funding from the ARC and the NHMRC.
This article was originally published on The Conversation. Read the original article.


New Mexico Measles Outbreak Cost Reached $5.4 Million, Study Finds
France Battles Mediterranean Wildfires as Heatwave Fuels Fire Risk
FDA Weighs Safety Standards for Psychedelic Therapies
France Keeps Top Health Alert as Officials Brace for Another Heatwave
Hanmi Pharm Soars 30% on $2.3 Billion Genentech Obesity Drug Deal
Moderna Wins FDA Approval for mFLUSIVA mRNA Flu Vaccine for Adults 50+
AstraZeneca Halts Phase III Volrustomig Lung Cancer Trial After Efficacy Setback
US-Backed Pediatric HIV Treatment Drops After Foreign Aid Changes, Study Finds
Novo Nordisk Strikes €1.17 Billion Nanexa Drug Delivery Deal
The government is ‘doubling down’ on its social media ban. But bigger penalties for platforms aren’t enough
Eli Lilly Eyes AtaiBeckley Acquisition to Expand Psychedelic Mental Health Pipeline
Novartis M&A Strategy Faces Investor Scrutiny After Drug Setbacks
U.S. Issues Cuba Health Alert as Illnesses Rise
SK Biopharmaceuticals Secures Global Rights to Biohaven Epilepsy Drug Opakalim 



